Aktuella utlysningar, vecka 7, 2023
Grants Office tipsar om aktuella utlysningar.
Svenska och nordiska anslag
Forskningsprojekt – Jane och Dan Olssons Stiftelse för Vetenskapliga Ändamål
Stiftelsen ändamål är att främja medicinsk vetenskaplig forskning i Sverige eller utomlands rörande barnlöshet och barns hälsa.
OBS! Ansökan skall skickas in med vanlig post.
Closing date: March 1, 2023
Research Grant – Foundation to Prevent Antibiotic Resistance
Grants aim to support research projects that will increase knowledge for preventing and managing bacterial infections and antibiotic resistance with new methods.
Closing date: March 24, 2023
Uppstartsbidrag - Barncancerfonden
Barncancerfonden utlyser uppstartsbidrag för internationella, fas III/IV multicenterstudier för behandling av barncancer. Syftet är att snabbt komma i gång med studierna i Sverige och att fler barn i Sverige ska ges möjlighet att behandlas inom ramen för en studie.
Closing date: Utlysningen är öppen under hela året, inkomna ansökningar behandlas löpande.
Forskningsanslag - Stiftelsen Serafimerlasarettet
Stiftelsen Serafimerlasarettet, grundad genom enskild offervillighet och i verksamhet sedan 1752, har till uppgift att främja medicinsk forskning och utbildning av läkare samt ändamål, som har samband med Serafimerlasarettets historia.
Stiftelsen utdelar medel för medicinsk forskning med tydlig klinisk inriktning och som bedrivs av yngre forskare (högst 45 års ålder eller högst 10 år efter disputation) vid Karolinska Institutet. Totalt utdelas ca 50-100 tkr till 3-4 forskare.
Stiftelsens ansökningsblankett skall användas. Ofullständig ansökan beaktas ej. Anslag för ett forskningsprojekt utgår för högst 3 år. Signerad ansökan skickas som pdf-fil senast den 30:e april 2023 till Chatrin Lindahl
Closing date: April 30, 2023
Lisa och Johan Grönbergs stiftelse
Lisa och Johan Grönbergs Stiftelse avser att dela ut ett antal anslag om max 150 000 kronor per anslag till disputerade forskare. Årets ämne är ”Metabolism vid stress – kliniska studier”. Humanstudier skall ingå i ansökan. Ansökningstiden är öppen från den 1 mars.
Closing date: March 31, 2023
Research Grants - Human Frontier Science Program Organization
HFSP Research Grants support innovative basic research into fundamental biological problems with emphasis placed on novel and interdisciplinary approaches that involve scientific exchanges across national and disciplinary boundaries.
Research grants are provided for teams of scientists from different countries who wish to combine their expertise in innovative approaches to questions that could not be answered by individual laboratories. Preliminary results are not required and applicants are expected to develop new lines of research through the research collaboration.
Two types of Grant are available:
- Research Grants – Program (RG-Program): to allow teams of independent researchers to develop new lines of research through a new collaboration, with applications including independent investigators early in their careers being particularly encouraged;
- Research Grants – Early Career: to enable teams of young investigators who are directing a research group to initiate and direct their own independent lines of research.
Closing date (Letter of Intent): 21 March 2023
Young investigator programme - European Molecular Biology Organisation (EMBO)
The European Molecular Biology Organisation invites applications for its young investigator programme. This supports life scientists who have been group leaders for less than four years at the time of application in setting up their laboratories. Young Investigators receive financial support for networking for four years and benefit from training opportunities, support for their lab members and mentoring. They become part of an international network of more than 600 current and former EMBO Young Investigators, Installation Grantees and Global Investigators.
Closing date: 01 April 2023
Andrew K Burroughs short-term training fellowship - European Association for the Study of the Liver (EASL)
The European Association for the Study of the Liver invites applications for the Andrew K Burroughs short-term training fellowship programme. This enables postgraduate investigators, who intend to spend time at a foreign institution in Europe, to accomplish a very focused research project, to learn an experimental procedure or methodology, or to get in-depth knowledge about a sophisticated, clinical diagnostic procedure not available at their home institution.
Members of the association who hold an MD or PhD degree and are no more than 40 years of age may apply. They may be of any nationality and be both basic or clinical investigators. The research supervisor at the hosting institution must be a member of the association but must not be a member of its governing board. No more than one application per hosting and home department is considered for a period of two years following the grant allocation.
Fellowships are worth €3,000 per month for up to six months.
Closing date: 30 March 2023
International 3Rs prize - National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)
The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) invites nominations for its international 3Rs prize. This recognises an original medical, biological or veterinary research paper published in the last three years that has or could have major impacts on the replacement, refinement or reduction of the use of animals in research
Closing date: 05 April 2023
Federal Funding agencies
Notice of Special Interest: Collaborative Studies on Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD): NIH
This Notice of Special Interest (NOSI) facilitates collaborative, cross-disciplinary, and multi-institutional approaches that will contribute new and vital information and insights about normal aging and the clinical and pathological course of AD/ADRD and/or that can advance the research agendas in any of the eight focus areas outlined in the AD/ADRD Research Implementation Milestones. Specifically, this NOSI solicits R01 applications that address its overarching objectives: 1) to promote the wider sharing and leveraging of NIA’s existing AD/ADRD resources by facilitating access to unique resources (such as the availability of neuropathological data on thousands of participants) and the collection and integration of new data and samples, and 2) to broaden the participation of researchers in the design, analysis, and interpretation of results from collaborative research that makes use of these unique resources to answer novel scientific questions.
Application and Submission Information: This notice applies to due dates through November 13, 2024.
Submit applications for this initiative using the following funding opportunity announcement (FOA) or any reissue of the announcement through the expiration date of this notice.
- PAR-22-093 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)
Notice Number: NOT-AG-21-035
2023 Amyotrophic Lateral Sclerosis Research Program (Congressionally Directed Medical Research Programs): DoD
The FY23 appropriation is $40.0M. Currently there are four award mechanisms are being solicited.
- Pilot Clinical Trial Award
- Supports exploratory clinical trials of novel therapeutics to demonstrate feasibility and inform the design of more advanced trials in amyotrophic lateral sclerosis (ALS).
- Must support a clinical trial and may not be used for preclinical research studies.
- The maximum allowable funding for the entire period of performance is $1,000,000 to $2,000,000 for direct costs and up to three years.
- Clinical Biomarker Development Award
- Supports development or improvement of clinical biomarkers to enrich clinical trials in ALS.
- The maximum allowable funding for the entire period of performance is $750,000 for direct costs and up to two years.
- Therapeutic Development Award
- Supports secondary preclinical validation and Investigational New Drug (IND)-enabling studies of therapeutics for ALS.
- The maximum allowable funding for the entire period of performance is $1,500,000 for direct costs and up to three years.
- Therapeutic Idea Award
- Supports highly innovative, hypothesis-driven preclinical therapeutic development in ALS.
- The maximum allowable funding for the entire period of performance is $600,000 to $750,000 for direct costs and up to two years.
- Pilot Clinical Trial Award: April 13, 2023 (Pre-application); July 13, 2023 (Full application).
- Clinical Biomarker Development Award: April 13, 2023 (Pre-application); July 13, 2023 (Full application).
- Therapeutic Development Award: April 13, 2023 (Pre-application); July 13, 2023 (Full application).
- Therapeutic Idea Award: April 13, 2023 (Pre-application); July 13, 2023 (Full application).
Funding Opportunity Announcement (FOA):
- Pilot Clinical Trial Award: HT9425-23-ALSRP-PCTA
- Clinical Biomarker Development Award: HT9425-23-ALSRP-CBDA
- Therapeutic Development Award: HT9425-23-ALSRP-TDA
- Therapeutic Idea Award: HT9425-23-ALSRP-TIA
2023 Epilepsy Research Program (Congressionally Directed Medical Research Programs): DoD
The FY23 appropriation is $12.0M. The ERP encourages collaboration among post-traumatic epilepsy (PTE) researchers and urges the scientific community to utilize equitable partnerships with people living with PTE to maximize the translational and impact potential of proposed research.
Funding Opportunity Announcement (FOA):
- Idea Development Award
- This is to solicit novel, innovative research that has the potential to increase our understanding of PTE to improve quality of life, especially in Service Members, Veterans, and/or their care partners. The work should innovatively challenge existing research paradigms or exhibit high levels of creativity.
- The maximum allowable funding for the entire period of performance is $450,000 to $650,000 for direct costs and up to three years.
- Research Partnership Award
- To create an avenue to support new or existing collaborative research partnerships between/among investigators to address a research problem or question in a manner that would be unachievable through separate efforts. It is expected that investigators utilize their distinct but complementary perspectives to synergistically address a central problem or question critical to PTE research and those living with PTE, their families, and/or their care partners.
- The maximum allowable funding for the entire period of performance is $1,200,000 for direct costs and up to three years.
- Virtual Post-Traumatic Epilepsy Research Center Faculty Award
- The P-TERC is a unique, interactive virtual research center providing intensive mentoring, national networking, collaborations, and a peer group for new PTE investigators. The overarching goal of the Virtual P-TERC is to develop successful, highly productive PTE researchers in a collaborative research and career development environment to enhance quality and expand quantity of the PTE research field.
- The maximum allowable funding for the entire period of performance is $525,000 for direct costs and up to three years.
- Leveraging Research Award
- To support research that leverages ongoing or completed research studies for which PTE was not an original focus and to provide support to expand the research to develop such a focus and increase our understanding of PTE. The project may include basic, translational, and/or clinical research studies.
- The maximum allowable funding for the entire period of performance is $250,000 for direct costs and up to three years.
- Idea Development Award: May 19, 2023 (Pre-Application); June 23, 2023 (Full proposal).
- Research Partnership Award: May 19, 2023 (Pre-Application); June 23, 2023 (Full proposal).
- Virtual Post-Traumatic Epilepsy Research Center Faculty Award: May 19, 2023 (Pre-Application); June 23, 2023 (Full proposal).
- Leveraging Research Award: May 19, 2023 (Pre-Application); June 23, 2023 (Full proposal).
Funding Opportunity Announcement (FOA):
- Idea Development Award: HT9425-23-ERP-IDA
- Research Partnership Award: HT9425-23-ERP-RPA
- Virtual Post-Traumatic Epilepsy Research Center Faculty Award: HT9425-23-ERP-VIRTUAL-P-TERC-F
- Leveraging Research Award: HT9425-23-ERP-LRA
In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed): NIH
The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member. The mission of IMPC is to generate a comprehensive catalogue of mammalian gene function that will provide the foundation for functional analyses of human genetic variation. The current (July 19, 2022) IMPC data release includes phenotypic data for 8260 knockout genes. Overall, the IMPC hopes to generate a null mutant and undertake broad-based phenotyping for every gene in the mouse genome. About 30% of these strains are expected to be either embryonic or perinatal lethal, or subviable. However, a large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes. The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult mouse phenotyping effort to perform additional in-depth phenotyping and research.
Deadline: standard due dates until January 08, 2026. Applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): PAR-23-074
Early and Late Stage Clinical Trials for the Spectrum of Alzheimer’s Disease/Alzheimer’s Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional): NIH
The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite applications that propose to develop and implement early to late stage clinical trials of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD) across the spectrum from pre-symptomatic to more severe stages of disease, and 2) stimulate studies to enhance trial design and methods.
Deadline: standard due dates until January 08, 2025. Applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): PAR-23-081
2023 Requests for Proposals, Lung Cancer Research Foundation(LCRF), US
The LCRF grant program provides funding for research into the prevention, diagnosis, treatment and cure of lung cancer.
- LCRF Leading Edge Research Grant Program:
- o This program seeks to fund innovative projects across the full spectrum of basic, translational, clinical, epidemiological, health services, early detection, disparities, and social determinants of health research. This funding mechanism seeks novel ideas, approaches, methods, and techniques that promise to have a profound impact on lung cancer patients and their treatment teams.
- LCRF Minority Career Development Award (CDA) in Lung Cancer
- This program is a two-year career development award intended to support early-stage scientists from underrepresented groups working in lung cancer in diverse areas of research including basic, clinical, translational, disparities, and social determinants of health research.
- LCRF Research Grant on Early Detection and Pre-Neoplasia in Lung Cancer
- This program is focused on identifying, characterizing, and developing approaches that will detect lung cancer at the earliest stages.
- LCRF Research Grants on Understanding Resistance in Lung Cancer
- This program will focus on understanding resistance and support research projects with an emphasis on characterizing, identifying, treating, overcoming, or preventing resistance to therapies in lung tumor cells, tissues, mouse models, or patients.
Each of these funding mechanisms will award $150,000 over two years for selected projects, and all mechanisms except the LCRF Minority Career Development Award will be reviewed through a two-step process (LoI and Full proposal).
Deadlines: March 10, 2023 (Letter of Intent). Full proposal is selected by invitation only.
LCRF Minority Career Development Award: May 31, 2023 (Full Proposal)
Alzheimer's Association Research Grant - New to the Field (AARG-NTF), US
The AARG-NTF grant program aims to fund investigators who are new to Alzheimer's and all other dementia fields of research, including neuroscience or neurodegeneration (Alzheimer's, Parkinson's, Lewy body dementia, etc.), and provide them with funding to establish a research path in Alzheimer's and all other dementias, to develop preliminary or pilot data, to test procedures and to develop hypotheses. Each AARG-NTF award total is limited to $200,000 (direct and indirect costs) for up to three years
Deadlines: March 6, 2023 (Letter of Intent); May 4, 2023 (Full proposal); Prior to August 30, 2023 (Award Notification).